US Patent Issued to The Medical College of Wisconsin on May 12 for "Targeting CLPTM1L for treatment and prevention of cancer" (Wisconsin Inventor)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,622,976, issued on May 12, was assigned to The Medical College of Wisconsin Inc. (Milwaukee).

"Targeting CLPTM1L for treatment and prevention of cancer" was invented by Michael A. James (Big Bend, Wis.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are therapeutic agents having specificity for human CLPTM1L/CRR9 polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic ...